Reading SNTI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SNTI free→Reading SNTI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SNTI free→NASDAQHealth CareBiotechnologySnapshot 2026-06-16
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is neutral, and management's recent track record has been fairly steady. The company was unprofitable over the past year, so its earnings quality can't be assessed, and risk is high. The sector backdrop is a headwind, which may affect SNTI's performance compared with sector peers, where it is typical. Peer multiples imply a price about 780% below where it trades (it looks expensive on this basis); the read is rich, as it trades above peer multiples, and the longer horizon does not make that back through growth. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 1 valuation methods, at three horizons. Current price $0.93. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
We can't anchor a clean multiple for SNTI right now, so treat our $0.10 fair value as low-confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 821% of near-term growth above a flat-multiple fair value; not enough history to forecast a comparison. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Flags: expensive valuation, a turbulent sector regime (Heating).
For similar setups historically (n=2,301): about 43% saw a 20%+ drawdown, and roughly 77% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted 0.72x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates.
8 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.28 → $-0.32 (-14.5% / 30d). 0 raised, 0 cut, 3 covering analysts.
0 upgrades, 0 downgrades / 30d. 100% of analysts rate Buy.
1 positive, 1 negative / 30d. See F4 management tile for the event list.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$282.
How much price usually moves either way.
On a bad day, this stock has moved -$833.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $7,301.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: If revenue growth in the health care sector speeds up, it may benefit Senti Biosciences.
Confirms:Health care sector revenue growth re-accelerates back toward its highs.
Disproves:Sector revenue growth is slowing down. This shows there are still challenges ahead.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for SNTI yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Entry into a Material Definitive Agreement—The Notes ” in the Company’s Current Report on Form 8-K filed by the Company on May 1, 2026 (the “Current Report”), which is incorporated herein by reference. In connection with the issuance and sale of the Notes on May 20, 2026, Acquiom Agency Services LLC was appointed collateral agent for the Notes, and the Form of Senior Secured Convertible Note of Senti Holdings, Inc. is re-filed herewith to reflect certain provisions added to the Note in connec…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Not enough peers to compare yet.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
SNTI Senti Biosciences Inc | Typical Show detailsSector percentile: 38 of 100 | expensive | high |
ABBV AbbVie | Above typical Show detailsSector percentile: 85 of 100 | fair | low |
AMGN Amgen | Above typical Show detailsSector percentile: 81 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 99 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 80 of 100 | expensive | moderate |
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Management is emphasizing capital allocation strategies, including direct financial obligations and private placements.
Management is actively pursuing M&A activities, including material definitive agreements.
Management aims to improve financial performance, as indicated by recent earnings announcements.
Results of Operations and Financial Condition. On May 14, 2026 , Senti Biosciences Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K. In accordance with General Instruction B.2. of Form 8-K, the information in this
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information contained above in
by reference. Assuming the issuance of the Initial Notes on the date hereof, the Issuance Approval and the immediate exchange of such Notes by Celadon for Company common stock, Celadon would, based on its Schedule 13D/A filed with the SEC on March 31, 2026, beneficially own 54.6% of the Company’s outstanding common stock. Celadon has agreed to pay an aggregate of $9.7 million for the Initial Notes, and the purchase price is expected to be funded by equity financing by Celadon. To the knowledg…
Entry Into a Material Definitive Agreement. Securities Purchase Agreement On April 27, 2026, Senti Biosciences Holdings, Inc. (the “Company”), Senti Holdings, Inc., a direct, wholly owned subsidiary of the Company (“Senti Holdings”), and Senti Biosciences, Inc., a direct wholly owned subsidiary of Senti Biosciences Holdings (“Senti Biosciences”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with one accredited investor (the “Investor”), pursuant to which…